Discontinuation of joint sales of NEOXY® Tape 73.5 mg
transdermal overactive bladder treatment medication
Hisamitsu Pharmaceutical Co., Inc.
Asahi Kasei Pharma Corp.
Hisamitsu Pharmaceutical Co., Inc., (Head office: Tosu city, Saga Prefecture, Japan; President & CEO: Hirotaka Nakatomi; hereinafter referred to as Hisamitsu) and Asahi Kasei Pharma Corp. (Head office: Chiyoda-ku, Tokyo, Japan; President: Kazuyoshi Hori; hereinafter referred to as Asahi Kasei) reached agreement to discontinue their joint sales of NEOXY® Tape 73.5 mg, a transdermal overactive bladder treatment medication, on June 26, 2016.
While Hisamitsu and Asahi Kasei have jointly sold NEOXY® Tape 73.5 mg since June 2013, the agreement to discontinue joint sales was reached as a result of discussion between the two companies. Asahi Kasei will discontinue sales within three months from June 26, 2016, when its inventory of NEOXY® Tape 73.5 mg is depleted. After that, Hisamitsu will sell NEOXY® Tape 73.5 mg alone.
Reference:
| Trade name | NEOXY® Tape 73.5 mg |
| Active pharmaceutical ingredient | Oxybutynin hydrochloride |
| Indication | Urinary urgency, frequent urination, and urge urinary incontinence caused by overactive bladders |
| Dose and Administration | Usually apply one sheet (73.5 mg of oxybutynin hydrochloride) once a day on the lower abdomen, lower back, or thigh of an adult and replace every 24 hours. |
| Packaging | 70 sheets (1 sheet/pack × 70), 280 sheets (1 sheet/pack × 280) |
| NHI drug price | 194.80 yen/sheet |
| Date of approval for manufacturing and marketing | March 25, 2013 |
| Date of initial marketing in Japan | June 27, 2013 |
| Manufactured and distributed by | Hisamitsu Pharmaceutical Co., Inc. |